{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:54:54Z","timestamp":1791971694443,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"45","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.vaccine.2021.07.073","type":"journal-article","created":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T01:06:15Z","timestamp":1633482375000},"page":"6682-6690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Persisting antibody responses to Vi polysaccharide\u2013tetanus toxoid conjugate (Typbar TCV\u00ae) vaccine up to 7\u202fyears following primary vaccination of children\u202f&lt;\u202f2\u202fyears of age with, or without, a booster vaccination"],"prefix":"10.1016","volume":"39","author":[{"given":"Krishna Mohan","family":"Vadrevu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dugyala","family":"Raju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Rani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamshi","family":"Sarangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4646-4471","authenticated-orcid":false,"given":"Raches","family":"Ella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhuvaneswara","family":"Javvaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niranjana S.","family":"Mahantshetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar","family":"Battu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron M.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9973","key":"10.1016\/j.vaccine.2021.07.073_b0005","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/S0140-6736(13)62708-7","article-title":"Typhoid fever","volume":"385","author":"Wain","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.07.073_b0010","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00482-18","article-title":"The gathering storm: is untreatable typhoid fever on the way?","volume":"9","author":"Levine","year":"2018","journal-title":"mBio"},{"issue":"2","key":"10.1016\/j.vaccine.2021.07.073_b0015","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.vaccine.2018.04.022","article-title":"Typhoid vaccines: WHO position paper, March 2018 - Recommendations","volume":"37","author":"World Health Organization","year":"2019","journal-title":"Vaccine"},{"issue":"9180","key":"10.1016\/j.vaccine.2021.07.073_b0020","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0140-6736(98)09001-1","article-title":"Typhoid fever in children aged less than 5 years","volume":"354","author":"Sinha","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.07.073_b0025","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2471\/BLT.06.039818","article-title":"A study of typhoid fever in five Asian countries: disease burden and implications for controls","volume":"86","author":"Ochiai","year":"2008","journal-title":"Bull World Health Organ"},{"issue":"5","key":"10.1016\/j.vaccine.2021.07.073_b0030","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1586\/14760584.7.5.547","article-title":"Typhoid vaccination: the Asian experience","volume":"7","author":"DeRoeck","year":"2008","journal-title":"Exp Rev Vaccines"},{"key":"10.1016\/j.vaccine.2021.07.073_b0035","article-title":"Vaccines for preventing typhoid fever","volume":"5","author":"Milligan","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"36","key":"10.1016\/j.vaccine.2021.07.073_b0040","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1016\/j.vaccine.2012.06.015","article-title":"Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: a cluster randomized trial in Karachi, Pakistan","volume":"30","author":"Khan","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2021.07.073_b0045","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0264-410X(94)90194-5","article-title":"Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines","volume":"12","author":"Keitel","year":"1994","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2021.07.073_b0050","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1073\/pnas.1819612116","article-title":"On the mechanisms of conjugate vaccines","volume":"116","author":"Rappuoli","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2021.07.073_b0055","unstructured":"World Health Organization. Guidelines on the quality, safety and efficacy of typhoid conjugate vaccines. Available at https:\/\/www.who.int\/biologicals\/areas\/vaccines\/TRS_987_Annex3.pdf?ua=1. Accessed on October 31, 2018."},{"issue":"11","key":"10.1016\/j.vaccine.2021.07.073_b0060","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1586\/14760584.2013.845529","article-title":"Development of Vi conjugate - a new generation of typhoid vaccine","volume":"12","author":"Szu","year":"2013","journal-title":"Exp Rev Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2021.07.073_b0065","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/civ295","article-title":"Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV\u00ae) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study","volume":"61","author":"Mohan","year":"2015","journal-title":"Clin Infect Dis: Off Publ Infect Dis Soc Am"},{"issue":"4","key":"10.1016\/j.vaccine.2021.07.073_b0070","doi-asserted-by":"crossref","first-page":"e0004616","DOI":"10.1371\/journal.pntd.0004616","article-title":"The burden of typhoid and paratyphoid in India: systematic review and meta-analysis","volume":"10","author":"John","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2021.07.073_b0075","unstructured":"VaccZyme\u2122: Human Anti-Salmonella typhi Vi IgG Enzyme Immunoassay Kit. Product code: MK091. Available at www.bindingsite.com\/en\/discover\/immunoassays\/plasma-screening\/vaccine-response?disclaimer=1. Accessed on February 13th, 2019."},{"issue":"15","key":"10.1016\/j.vaccine.2021.07.073_b0080","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.vaccine.2013.02.006","article-title":"A human IgG anti-Vi reference for Salmonella typhi with weight-based antibody units assigned","volume":"31","author":"Szu","year":"2013","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.vaccine.2021.07.073_b0085","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.vaccine.2014.02.050","article-title":"Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children","volume":"32","author":"Szu","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.07.073_b0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.biologicals.2018.09.001","article-title":"Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG","volume":"56","author":"Rijpkema","year":"2018","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2021.07.073_b0095","unstructured":"First International standard for Anti-Typhoid capsular Vi polysaccharide IgG (Human), WHO International Standard, NIBSC code: 16\/138. Available at https:\/\/www.nibsc.org\/documents\/ifu\/16-138.pdf. Accessed on 04 Jan 2020. ."},{"issue":"10111","key":"10.1016\/j.vaccine.2021.07.073_b0100","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/S0140-6736(17)32149-9","article-title":"Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial","volume":"390","author":"Jin","year":"2017","journal-title":"The Lancet"},{"issue":"23","key":"10.1016\/j.vaccine.2021.07.073_b0105","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1905047","article-title":"Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal","volume":"381","author":"Shakya","year":"2019","journal-title":"N Engl J Med"},{"issue":"10301","key":"10.1016\/j.vaccine.2021.07.073_b0110","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(21)01124-7","article-title":"Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial","volume":"398","author":"Qadri","year":"2021","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.vaccine.2021.07.073_b0115","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJM200104263441701","article-title":"The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children","volume":"344","author":"Lin","year":"2001","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.vaccine.2021.07.073_b0120","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1056\/NEJM200310023491423","article-title":"Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children","volume":"349","author":"Lanh","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.07.073_b9000","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1056\/NEJM200310023491423","article-title":"Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children","volume":"349","author":"Mai","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.07.073_b0125","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.biologicals.2020.05.002","article-title":"Evaluation of a standardised Vi poly-l-lysine ELISA for serology of Vi capsular polysaccharide antibodies","volume":"66","author":"Rigsby","year":"2020","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2021.07.073_b0130","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.biologicals.2018.09.001","article-title":"Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG","volume":"56","author":"Rijpkema","year":"2018","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2021.07.073_b0135","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4269\/ajtmh.18-0139","article-title":"Longitudinal typhoid fever trends in India from 2000 to 2015","volume":"99","author":"Balaji","year":"2018","journal-title":"Am J Trop Med Hygiene"},{"key":"10.1016\/j.vaccine.2021.07.073_b0140","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1093\/infdis\/jiy502","article-title":"A retrospective review of hospital-based data on enteric fever in India, 2014\u20132015","volume":"218","author":"Sur","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.07.073_b0145","unstructured":"State-wise Cases and Deaths due to Enteric Fever (Typhoid) reported during 2014\u2013 2016, Ministry of Health, Govt of India, accessed on May 6th, 2020. Available at http:\/\/www.indiaenvironmentportal.org.in\/files\/file\/WATER%20BORNE%20DISEASES.pdf."},{"issue":"12","key":"10.1016\/j.vaccine.2021.07.073_b0150","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1128\/jcm.25.12.2266-2269.1987","article-title":"Development and evaluation of an enzyme-linked immunosorbent assay for serum Vi antibodies for detection of chronic Salmonella typhi carriers","volume":"25","author":"Losonsky","year":"1987","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2021.07.073_b0155","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.3389\/fimmu.2019.02582","article-title":"IgA and IgG1 specific to vi polysaccharide of salmonella typhi correlate with protection status in a typhoid fever controlled human infection model","volume":"10","author":"Dahora","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2021.07.073_b0160","unstructured":"WHO Summary of the October 2017 meeting of the Strategic Advisory Group of Experts on Immunization [cited 2018 Nov 13]. Available from www.who.int\/immunization\/sage\/meetings\/2017\/october\/1_Typhoid_SAGE_background_paper_Final_v3B.pdf."},{"key":"10.1016\/j.vaccine.2021.07.073_b0165","unstructured":"WHO prequalified vaccines aoN, 2018, Available from, http:\/\/www.who.int\/immunization_standards\/vaccine_quality\/PQ_vaccine_list_en\/en\/."},{"key":"10.1016\/j.vaccine.2021.07.073_b0170","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.1016\/j.vaccine.2017.08.001","volume":"35","author":"Meiring","year":"2017","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2021.07.073_b0175","doi-asserted-by":"crossref","first-page":"e927","DOI":"10.1093\/cid\/ciab059","article-title":"Evaluation of vaccine safety after the first public sector introduction of typhoid conjugate vaccine-Navi Mumbai, India, 2018","volume":"73","author":"Longley","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.07.073_b0180","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1093\/cid\/ciaa314","article-title":"Tenacious endemic typhoid fever in Samoa","volume":"71","author":"Sikorski","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2021.07.073_b0185","doi-asserted-by":"crossref","first-page":"e0005376","DOI":"10.1371\/journal.pntd.0005376","article-title":"The burden of typhoid fever in low- and middle-income countries: a meta-regression approach","volume":"11","author":"Antill\u00f3n","year":"2017","journal-title":"PLoS Negl Trop Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2100966X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2100966X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:02:30Z","timestamp":1759402950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2100966X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":38,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0264410X2100966X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.07.073","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persisting antibody responses to Vi polysaccharide\u2013tetanus toxoid conjugate (Typbar TCV\u00ae) vaccine up to 7\u202fyears following primary vaccination of children\u202f<\u202f2\u202fyears of age with, or without, a booster vaccination","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.07.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}